Article
BAMM (BRAF Autophagy and MEK Inhibition in Melanoma): A Phase I/II Trial of Dabrafenib, Trametinib, and Hydroxychloroquine in Advanced BRAFV600-mutant Melanoma.
Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Mar 2022
Mehnert Janice M, Mitchell Tara C, Huang Alexander C, Aleman Tomas S, Kim Benjamin J, Schuchter Lynn M, Linette Gerald P, Karakousis Giorgos C, Mitnick Sheryl, Giles Lydia, Carberry Mary, Frey Noelle, Kossenkov Andrew, Groisberg Roman, Hernandez-Aya Leonel F, Ansstas George, Silk Ann W, Chandra Sunandana, Sosman Jeffrey A, Gimotty Phyllis A, Mick Rosemarie, Amaravadi Ravi K
Abstract excerpt
PURPOSE: Autophagy is a resistance mechanism to BRAF/MEK inhibition in BRAFV600-mutant melanoma. Here we used hydroxychloroquine (HCQ) to inhibit autophagy in combination with dabrafenib 150 mg twice daily and trametinib 2 mg every day (D+T). PATIENTS AND METHODS: We conducted a phase I/II clinical trial in four centers of HCQ + D+T in patients with advanced BRAFV600-mutant melanoma. The primary objectives were...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.